Literature DB >> 2570704

Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.

M Johnson1, G R Hanson, J W Gibb.   

Abstract

The role of N-methyl-D-aspartate (NMDA) receptors in the decrease in neostriatal tryptophan hydroxylase (TPH) activity induced by repeated high doses of methamphetamine or 3,4-methylenedioxymethamphetamine (MDMA) was evaluated. Rats received 4 injections of methamphetamine (15 mg/kg) or MDMA (10 mg/kg) at 6 h intervals, and were killed 18-20 h after the last administration. These treatments with methamphetamine or MDMA reduced neostriatal TPH activity to 26 and 34% of control, respectively. Coadministration of MK-801 (2.5 mg/kg) significantly attenuated the methamphetamine-induced decrease in TPH activity (66% of control), but did not alter the effect of MDMA. This study suggests that excitatory amino acids may participate in the methamphetamine-induced decline in central TPH activity, and that the mechanism by which MDMA and methamphetamine decreases TPH activity may differ.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570704     DOI: 10.1016/0014-2999(89)90728-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.

Authors:  M I Colado; T K Murray; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

2.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

3.  Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions.

Authors:  T Ohmori; T Koyama; A Muraki; I Yamashita
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine.

Authors:  H A Baldwin; M I Colado; T K Murray; R J De Souza; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

5.  Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity.

Authors:  J F Marshall; S J O'Dell; F B Weihmuller
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Effects of nitric oxide synthesis inhibition on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain.

Authors:  T Abekawa; T Ohmori; T Koyama
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.

Authors:  Jean Lud Cadet; Irina N Krasnova; Subramaniam Jayanthi; Johnalyn Lyles
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

Review 8.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

9.  Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats.

Authors:  Anna M S Kindlundh-Högberg; Anna Blomqvist; Rana Malki; Helgi B Schiöth
Journal:  BMC Neurosci       Date:  2008-04-17       Impact factor: 3.288

10.  Proteomic Profiling Reveals the Molecular Changes of Insomnia Patients.

Authors:  Guanying Wang; Xiaojuan Ren; Xingping Zhang; Qingquan Wang; Tao Liu; Ning Deng; Deqi Yan
Journal:  Biomed Res Int       Date:  2021-01-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.